Skip to main content

Table 3 Frequency of symptoms between two groups in three measurement status

From: Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial

Variable Group Start time
N (%)
3rd month
N (%)
9th month
N (%)
Fibrillation Drug    
0 18 (100) 7 (38.9) 16 (88.9)
1+ 0 (0) 2 (11.1) 0 (0)
2+ 0 (0) 7 (38.9) 2 (11.1)
3+ 0 (0) 7 (11.1) 0 (0)
Placebo    
0 18 (100) 6 (33.3) 14 (77.8)
1+ 0 (0) 3 (16.7) 2 (11.1)
2+ 0 (0) 6 (33.3) 2 (11.1)
3+ 0 (0) 3 (16.7) 0 (0)
Numbness Drug 0 (0) 12 (66.7) 2 (11.1)
Placebo 0 (0) 12 (66.7) 4 (22.2)
Tingling Drug 0 (0) 18 (100) 11 (61.1)
Placebo 0 (0) 18 (100) 12 (66.7)
Freezing Drug 0 (0) 12 (66.7) 10 (55.6)
Placebo 0 (0) 12 (66.7) 10 (55.6)
Sensitivity to touch Drug 0 (0) 2 (11.1) 0 (0)
Placebo 0 (0) 6 (33.3) 0 (0)
Muscle weakness Drug 0 (0) 1 (5.6) 0 (0)
Placebo 0 (0) 1 (5.6) 0 (0)
Elbow reflex Drug 18 (100) 17 (94.4) 17 (94.4)
Placebo 18 (100) 14 (77.8) 18 (100)
Knee reflex Drug 18 (100) 16 (88.9) 18 (100)
Placebo 18 (100) 15 (83.3) 17 (94.4)